Juluca

Dolutegravir sodium and rilpivirine hydrochloride, the active ingredients in Juluca, are an integrase strand transfer inhibitor and a non‑nucleoside reverse transcriptase inhibitor presented as an oral tablet for systemic use. It treats HIV‑1 infection in treatment‑experienced adults.

GNH USA supplies Juluca as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Juluca is an antiretroviral medication that targets HIV‑1 replication in adults who have previously received therapy.

HIV‑1 infection in treatment‑experienced adults: provides virologic suppression when combined with a suitable background regimen.

Juluca may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Nausea: mild stomach upset reported by some patients. - Headache: transient headache episodes. - Fatigue: feeling of tiredness or reduced energy. - Diarrhea: loose stools, usually self‑limiting. - Insomnia: difficulty falling or staying asleep. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice. - Severe hypersensitivity: swelling, breathing difficulty, or anaphylaxis. - QT prolongation: cardiac rhythm changes detectable on ECG. - Depression or mood changes: new or worsening psychiatric symptoms. - Elevated serum creatinine: indicating possible renal impact. - Pancreatitis: abdominal pain with elevated enzymes.

Before initiating Juluca, consider the following safety measures.

Baseline liver function: assess hepatic enzymes to detect pre‑existing liver disease. Drug resistance testing: ensure no prior resistance to integrase inhibitors or NNRTIs. Concomitant medications: review for potential interactions that affect drug levels. Pregnancy and breastfeeding: discuss risks with a healthcare professional. Adherence counseling: emphasize the importance of consistent daily dosing. Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Juluca can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce rilpivirine absorption. - Rifampin or other strong enzyme inducers: markedly lower dolutegravir levels. - Proton pump inhibitors: may decrease rilpivirine exposure.

Moderate Interactions (Monitor Closely): - Certain anticonvulsants (e.g., carbamazepine): modestly reduce dolutegravir concentrations. - St. John’s wort: may lower rilpivirine levels. - Hormonal contraceptives: potential reduction in efficacy, consider alternative methods.